SAM
RVNC

Sectoral Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Sectoral Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-11,234
Closed -$146K – 85
2019
Q2 		$146K Hold
11,234
– – 0.02% 80
2019
Q1 		$177K Hold
11,234
– – 0.02% 90
2018
Q4 		$226K Hold
11,234
– – 0.03% 84
2018
Q3 		$279K Buy
+11,234
New +$306K 0.03% 116

Other funds holding RVNC

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return

Sectoral Asset Management's RVNC Position: Q3 2019 in Review

Sectoral Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2019, closing a stake of 11,234 shares — an estimated $146K sold.

Sectoral Asset Management first reported a position in RVNC in Q3 2018 and held it in 4 quarters. The position peaked at $279K in Q3 2018. 109 funds tracked by Wall St. Rank hold RVNC as of Q3 2019.

  • Sectoral Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • Sectoral Asset Management sold 11,234 Revance Therapeutics, Inc. shares in Q3 2019, an estimated $146K.
  • Sectoral Asset Management first reported a position in Revance Therapeutics, Inc. in Q3 2018 and held it in 4 quarters.
  • Sectoral Asset Management's Revance Therapeutics, Inc. position peaked at $279K in Q3 2018.
  • 109 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2019.

Based on Sectoral Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.